H.C. Wainwright analyst Douglas Tsao says Alkermes' (ALKS) settlement and license agreement with Amneal Pharmaceuticals (AMRX) provides a "measure of needed visibility." There was some investor nervousness coming into the hearing and this settlement "represents close to a best-case scenario for Alkermes," Tsao tells investors in a research note. Vivitrol's growth has slowed but 12% volume growth in Q2 indicates the franchise can continue to be a contributor for the foreseeable future, adds the analyst. Tsao thinks the bull thesis for Alkermes hinges largely on the prospects for ALKS-4230. The update that patients on ALKS-4230 appear to avoid capillary leak syndrome, which has limited the utility of IL-2 therapies in the past, is important, according to Tsao. He keeps a Neutral rating on Alkermes with a $28 price target.